Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.

MLA

Vannucchi, Alessandro M., et al. “Compassionate Use of JAK1/2 Inhibitor Ruxolitinib for Severe COVID-19: A Prospective Observational Study.” Leukemia, vol. 35, no. 4, Apr. 2021, pp. 1121–33. EBSCOhost, https://doi.org/10.1038/s41375-020-01018-y.

APA

Vannucchi, A. M., Sordi, B., Morettini, A., Nozzoli, C., Poggesi, L., Pieralli, F., Bartoloni, A., Atanasio, A., Miselli, F., Paoli, C., Loscocco, G. G., Fanelli, A., Para, O., Berni, A., Tassinari, I., Zammarchi, L., Maggi, L., Mazzoni, A., Scotti, V., … Guglielmelli, P. (2021). Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia, 35(4), 1121–1133. https://doi.org/10.1038/s41375-020-01018-y

Chicago

Vannucchi, Alessandro M, Benedetta Sordi, Alessandro Morettini, Carlo Nozzoli, Loredana Poggesi, Filippo Pieralli, Alessandro Bartoloni, et al. 2021. “Compassionate Use of JAK1/2 Inhibitor Ruxolitinib for Severe COVID-19: A Prospective Observational Study.” Leukemia 35 (4): 1121–33. doi:10.1038/s41375-020-01018-y.